More broadly, for patients with single advanced malignancies expressing PD-L1 representing approximately 20% of TNBC (14) and 50% of Merkel-cell carcinomas (15), this risk-stratification methodology can guide clinicians in weighing chemotherapy toxicity against immunotherapy benefits. The gene discussed is CD274; the disease is Merkel cell skin cancer.